These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32279598)

  • 21. Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma.
    Cai H; Zhang L; Li N; Zheng B; Liu M
    Leuk Lymphoma; 2019 Dec; 60(12):2951-2959. PubMed ID: 31161831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.
    Kumar SK; LaPlant B; Roy V; Reeder CB; Lacy MQ; Gertz MA; Laumann K; Thompson MA; Witzig TE; Buadi FK; Rivera CE; Mikhael JR; Bergsagel PL; Kapoor P; Hwa L; Fonseca R; Stewart AK; Chanan-Khan A; Rajkumar SV; Dispenzieri A
    Blood Cancer J; 2015 Aug; 5(8):e338. PubMed ID: 26275080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ixazomib: a novel drug for multiple myeloma.
    Zanwar S; Abeykoon JP; Kapoor P
    Expert Rev Hematol; 2018 Oct; 11(10):761-771. PubMed ID: 30173621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland.
    Mankinen P; Vihervaara V; Torvinen S; Martikainen J; Soini E
    J Med Econ; 2019 Apr; 22(4):328-335. PubMed ID: 30644325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
    Manda S; Yimer HA; Noga SJ; Girnius S; Yasenchak CA; Charu V; Lyons R; Aiello J; Bogard K; Ferrari RH; Cherepanov D; Demers B; Lu V; Whidden P; Kambhampati S; Birhiray RE; Jhangiani HS; Boccia R; Rifkin RM
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e910-e925. PubMed ID: 32912820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
    Richardson PG; Baz R; Wang M; Jakubowiak AJ; Laubach JP; Harvey RD; Talpaz M; Berg D; Liu G; Yu J; Gupta N; Di Bacco A; Hui AM; Lonial S
    Blood; 2014 Aug; 124(7):1038-46. PubMed ID: 24920586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.
    San-Miguel JF; Echeveste Gutierrez MA; Špicka I; Mateos MV; Song K; Craig MD; Bladé J; Hájek R; Chen C; Di Bacco A; Estevam J; Gupta N; Byrne C; Lu V; van de Velde H; Lonial S
    Haematologica; 2018 Sep; 103(9):1518-1526. PubMed ID: 29954932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
    Engür S; Dikmen M
    Acta Clin Belg; 2017 Dec; 72(6):391-398. PubMed ID: 28327055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteasome inhibitors for the treatment of multiple myeloma.
    Scalzulli E; Grammatico S; Vozella F; Petrucci MT
    Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study.
    Lassalle A; Thomaré P; Fronteau C; Mahé B; Jubé C; Blin N; Voldoire M; Dubruille V; Tessoulin B; Touzeau C; Chauvin C; Loirat M; Lok A; Bourcier J; Lestang E; Mocquet R; Barbarot V; Moreau P
    Ann Oncol; 2016 Feb; 27(2):314-8. PubMed ID: 26578729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
    Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
    J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient.
    Steiner RE; Orlowski RZ; Lee HC
    Acta Haematol; 2018; 139(1):67-70. PubMed ID: 29402766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
    Kumar SK; Bensinger WI; Zimmerman TM; Reeder CB; Berenson JR; Berg D; Hui AM; Gupta N; Di Bacco A; Yu J; Shou Y; Niesvizky R
    Blood; 2014 Aug; 124(7):1047-55. PubMed ID: 24904120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteasome inhibitors: structure and function.
    Nunes AT; Annunziata CM
    Semin Oncol; 2017 Dec; 44(6):377-380. PubMed ID: 29935898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
    Gupta N; Goh YT; Min CK; Lee JH; Kim K; Wong RS; Chim CS; Hanley MJ; Yang H; Venkatakrishnan K; Hui AM; Esseltine DL; Chng WJ
    J Hematol Oncol; 2015 Sep; 8():103. PubMed ID: 26337806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
    Gupta N; Yang H; Hanley MJ; Zhang S; Liu R; Kumar S; Richardson PG; Skacel T; Venkatakrishnan K
    Target Oncol; 2017 Oct; 12(5):643-654. PubMed ID: 28803351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
    Xu W; Sun X; Wang B; Guo H
    Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.
    Daniely D; Forouzan E; Spektor TM; Cohen A; Bitran JD; Chen G; Moezi MM; Bessudo A; Hrom J; Eshaghian S; Swift RA; Eades BM; Kim C; Lim S; Berenson JR
    Exp Hematol; 2022 Jul; 111():79-86. PubMed ID: 35417741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial.
    Schjesvold F; Goldschmidt H; Maisnar V; Spicka I; Abildgaard N; Rowlings P; Cain L; Romanus D; Suryanarayan K; Rajkumar V; Odom D; Gnanasakthy A; Dimopoulos M
    Eur J Haematol; 2020 May; 104(5):443-458. PubMed ID: 31880006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.